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This in vitro study describes a novel cell culture, transport, and transfer protocol that may be highly suitable
for delivering cultured proliferating keratinocytes and melanocytes to large open skin wounds (e.g., burns).
We have taken into account previous limitations identified using other keratinocyte transfer techniques, such
as regulatory issues, stability of keratinocytes during transport (single cell suspensions undergo terminal
differentiation), ease of handling during application, and the degree of epidermal blistering resulting after
transplantation (both related to transplanting keratinocyte sheets). Large numbers of proliferating epidermal
cells (EC) (keratinocytes and melanocytes) were generated within 10–14 days and seeded onto a three-
dimensional matrix composed of elastin and collagen types I, III, and V (Matriderm), which enabled easy
and stable transport of the EC for up to 24 h under ambient conditions. All culture conditions were in
accordance with the regulations set by the Dutch Central Committee on Research Involving Human Subjects
(CCMO). As an in vitro model system for clinical in vivo transfer, the EC were then transferred from
Matriderm onto human acellular dermis during a period of 3 days. After transfer the EC maintained the
ability to regenerate into a fully differentiated epidermis containing melanocytes on the human dermis.
Proliferating keratinocytes were located in the basal layer and keratin-10 expression was located in differenti-
ating suprabasal layers similar to that found in human epidermis. No blistering was observed (separation of
the epidermis from the basement membrane). Keratin-6 expression was strongly upregulated in the regenerat-
ing epidermis similar to normal wound healing. In summary, we show that EC-Matriderm contains viable,
metabolically active keratinocytes and melanocytes cultured in a manner that permits easy transportation and
contains epidermal cells with the potential to form a pigmented reconstructed epidermis. This in vitro study
has produced a robust protocol that is ready for clinical studies in the future.
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INTRODUCTION large wounds, the availability of donor site skin may be
a limiting factor. Alternative methods for closing large
wounds and in particular for reepithelializing theseOptimal closure of large cutaneous wounds such as
burns, trauma-induced wounds, and surgical excision wounds have been sought for many years. It is thought
that application of cultured epithelial cells in combina-wounds is still a major challenge for clinicians. Delayed
wound closure increases the risk of infection, dehydra- tion with a dermal matrix may provide a future means
of obtaining superior wound healing while at the sametion, and adverse (hypertrophic) scar formation. There-
fore, the time taken for wound closure is very important time solving the problem when donor site skin is lim-
ited.for the final quality of the wound healing. Transplanta-
tion of full or split-thickness (often meshed) autograft is Application of cultured confluent autologous keratin-
ocyte sheets was the first alternative method used to re-still the most commonly used method for closing large
cutaneous wounds (2). However, results are often con- place split-thickness autograft, particularly for the treat-
ment of major burns. The method was developed bysidered suboptimal, particularly when expanded meshed
autografts are used. Also, when treating particularly Rheinwald and Green in 1975 (22) and the first applica-
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tion for treating extensive third-degree burns was in (Hyclone, UT, USA). Cells were then co-seeded into tis-
sue culture dishes coated with 0.5 µg/cm2 human placen-1981 (20). Whereas at the time this methodology pro-
vided a life-saving breakthrough for many patients, a tal collagen IV at a density of 3 × 106 cells per 9-cm-
diameter culture dish (Sigma-Aldrich, St. Louis, MO,number of major drawbacks have now been realized,
making it unacceptable for current medical and ethical USA) and cultured in keratinocyte culture medium at
37°C, 7.5% CO2. Keratinocyte culture medium consistedtesting committees. These drawbacks include the use of
lethally irradiated 3T3 murine fibroblasts in order to suf- of Dulbecco’s modified Eagle’s medium (DMEM)/
Ham’s F12 (Lonza, Verviers, Belgium) in a 3:1 ratioficiently amplify the yield of keratinocytes. Such cocul-
ture is accompanied with the risk of viruses, prions, or supplemented with 5% fetalclone III (Hyclone), 1 µmol/
L hydrocortisone (Sigma-Aldrich), 1 µmol/L isoprotere-other macromolecules being transmitted from the feeder
cells to the human cells during culture (5). In a previous nol hydrochloride (Sigma-Aldrich), 0.09 µmol/L insulin
(Sigma-Aldrich), 2 ng/ml human keratinocyte growthstudy we solved this problem by culturing keratinocytes
on collagen IV, which eliminated the requirement of factor (Sigma-Aldrich), 50 U/ml penicillin, and 50 U/ml
streptomycin (Lonza, Verviers, Belgium). The culturefeeder layer cells while still maintaining a satisfactory
amplification factor (7). medium was accepted by the Dutch Central Committee
on Research Involving Human Subjects (CCMO) asOther drawbacks with regard to the original Rhein-
wald and Green method include the use of high concen- suitable for culturing epidermal cells for use in human
clinical studies.trations of bovine serum in the culture medium, which
results in noncompliance with current regulatory re- After approximately 10–14 days of culture in which
the cultures were passaged twice, epidermal cells (kera-quirements; the extreme fragility of the sheets, which
makes transport logistics and application onto the wound tinocytes and melanocyte coculture) were seeded at a
density of 50,000 cells/cm2 onto Matriderm, a 10 × 15surface very difficult, and importantly the enzymatic
(dispase) digestion required to remove the sheets from cm collagen–elastin matrix (dr. Suwelack Skin & Health
Care, Billerbeck, Germany), which has the registrationthe tissue culture plastic, which results in poor and
highly variable take, and frequent blistering of the sheets as a medical device. Epidermal cell-loaded Matriderm
(EC-Matriderm) was further cultured at 37°C and 7.5%after application (2,3,6,8,13,14). In this study, we have
taken all of these previous drawbacks into account and CO2 for 3–5 days. For quality control, 3-mm-diameter
biopsies were taken from the EC-Matriderm for analyseshave developed a means to amplify large numbers of
proliferating epidermal cells (EC) (keratinocytes and by MTT assay (at least three biopsies were taken from
each of six independent donor experiments) and for (im-melanocytes) and a means to easily transport and finally
transfer the cells onto a dermal matrix, all in accordance muno)histological analysis. From three of these experi-
ments, 1-cm2 biopsies were also taken from each EC-with the regulations set by the Dutch Central Committee
on Research Involving Human Subjects (CCMO). This Matriderm in order to determine the transferability and
regenerative potential of the epidermal cells (three dif-in vitro study shows that a three-dimensional (3D) ma-
trix composed of elastin and collagen types I, III, and V ferent donors, in duplicate). A schematic diagram of the
protocol is shown in Figure 1.(Matriderm) can be used as an effective transport car-
rier system to enable easy transport and transfer of am-
Transport Conditions for EC-Matridermplified, proliferating EC (keratinocytes and melano-
cytes) onto human acellular dermis. After transfer we Three days after seeding EC onto Matriderm, the EC-
Matriderm was washed twice in Hank’s balanced saltshow that the EC can then regenerate to form a fully
differentiated epidermis containing melanocytes. solution (HBSS) (Lonza, Verviers, Belgium). Excess
fluid was removed and the EC-Matriderm was left under
MATERIALS AND METHODS
ambient transport conditions (20°C, atmospheric oxygen
Epidermal Cell Culture and humidity) for 24 h. After 24 h, the EC-Matriderm
received fresh keratinocyte culture medium and wasHuman adult skin was obtained from healthy donors
(with informed consent) undergoing abdominal dermoli- transferred to the culture incubator for a further 48 h in
order to determine whether the 24-h transport conditionpectomy and was used directly after surgery. The VU
University Medical Center approved of the experiments had long-lasting detrimental effects on cell metabolism
and survival. Biopsies (10 × 3 mm diameter) were takendescribed in this article.
From 3 cm2 full-thickness skin, epidermal sheets from different areas of the EC-Matriderm at time 0 (con-
trol), after 24 h at ambient condition, and after 48-h re-were separated from dermis by incubation in Dispase II
(Roche, Mannheim, Germany) overnight at 4°C. Kera- placement in the culture incubator. Biopsies were ana-
lyzed by MTT assay to determine metabolic activity andtinocytes and melanocytes were isolated from the epi-
dermis by incubating for 10 min in trypsin 0.125% cell survival. The values of the 10 biopsies obtained per
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Figure 1. Schematic diagram of the culture protocol.
experiment were averaged. The experiment was per- (Sigma-Aldrich), 1 µmol/L DL-α-tocopherol (Sigma-
Aldrich), and 0.4 mmol/L L-ascorbic acid (Sigma-Ald-formed with three different donors, each in duplicate.
rich), enriched with a lipid supplement containing 7
Transfer of Epidermal Cells From EC-Matriderm Onto µmol/L arachidonic acid (Sigma-Aldrich), 25 µmol/L
Human Dermis and Regeneration of the Epidermis palmitic acid (Sigma-Aldrich), 15 µmol/L linoleic acid
(Sigma-Aldrich), and 24 µmol/L bovine serum albuminAcellular human dermis was prepared from glycerol-
preserved donor skin obtained from Euro Skin Bank, (Sigma-Aldrich). Hereafter, cultures were harvested for
analysis of cell viability (MTT assay) and (immuno)his-(Beverwijk, The Netherlands) by repeated washing in
phosphate-buffered saline (PBS) as previously described tology.
(27). EC-Matriderm (1 cm2) was washed for 1 h with
MTT AssayHBSS and then laid onto the acellular dermis. After 3
days, EC-Matriderm was removed and the dermis with The MTT assay measures mitochondrial metabolic
activity. This assay is based on the cleavage of MTT [3-the transferred epidermal cells was cultured for a further
2 weeks at the air–liquid interface. Culture medium con- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] to formazan crystals by metabolic active cells.sisted of DMEM/Ham’s F12 in a 3:1 ratio supplemented
with 1% fetalclone III, 1 µmol/L hydrocortisone, 1 The amount of formazan crystals directly correlates to
the number of viable cells. Formazan crystals are solubi-µmol/L isoproterenol hydrochloride, 0.1 µmol/L insulin,
4 ng/ml keratinocyte growth factor human, 50 U/ml pen- lized and the resulting colored solution is quantified us-
ing an ELISA reader. In short, 3-mm biopsies of EC-icillin and 50 U/ml streptomycin, 10 µmol/L L-carnitine
hydrochloride (Sigma-Aldrich), 0.01 mol/L L-serine Matriderm or reconstructed epidermis on dermis were
transferred to a 96-well flat-bottom microtiter plate(Sigma-Aldrich), 1 ng/ml epidermal growth factor
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filled with 200 µl per well of 2 mg/ml MTT labeling different donors (Table 1). An average of 2.9 × 106
(±0.4 × 106) epidermal cells was isolated from each 1reagent (Roche, Penzberg, Germany). After incubation
for 2 h at 37°C the biopsies were transferred to a 96-well cm2 of skin. After 8–9 days, cultures had reached 80–
90% confluency and had amplified by a factor 1.6 ± 0.3.microtiter plate containing 200 µl per well isopropanol,
acidified with 0.04 M HCL (3:1) and incubated over- These subconfluent cultures were then passaged. After a
total culture period of 10–14 days, the amplification fac-night at room temperature. Extractant solution (100 µl)
was then transferred to a 96-well microtiter plate for op- tor was 5.4 ± 0.7 compared to the original cell number
obtained from a 1 cm2 skin biopsy. These passage 2 ker-tical density (OD) measurements at 550 nm and a refer-
ence wavelength of 650 nm. An absorbance above 0.05 atinocytes were seeded at a density of 50,000 keratino-
cytes/cm2 onto Matriderm, resulting in 319 ± 79-fold in-indicates mitochondrial activity and cell viability.
crease in surface area of the original 1-cm2 skin biopsy.Histology and Immunohistochemistry
EC-Matriderm had a standard surface area of 150 cm2
Samples were fixed in 4% formaldehyde and pro- (10 × 15 cm), which could be easily cut if required to
cessed for conventional paraffin embedment. Paraffin
accommodate the required seeding cell density.
sections of 5 µm thickness were cut, deparaffinized, and
rehydrated in preparation for morphological analysis Viability and Distribution of Epidermal Cells
(hematoxylin and eosin staining) or immunohistochemi- in EC-Matriderm
cal analysis of Ki67 (MIB-1, Dako, Glostrup, Denmark), When testing a new carrier system it is important to
keratin 6 (Ks6.KA12, IgG1 Progen, Heidelberg, Ger- determine whether the cells remain viable in the carrier
many), keratin 10 (DE K10, IgG1, ICN Biomedicals,
and whether the cells are distributed evenly throughout
Aurora, USA), and cytokeratin (LP34, IgG1 Dako, Glos- the carrier. Therefore, epidermal cells were cultured in
trup, Denmark). For detection of Ki67, keratin 6, keratin Matriderm for 3–5 days. Hereafter, multiple 3-mm biop-
10, and cytokeratin a standard method for antigen re-
sies were taken from different regions of EC-Matriderm
trieval on paraffin sections was performed. Sections
and metabolic activity/cell viability was determined with
were immersed in 0.01 M sodium citrate buffer (pH 6.0) the aid of an MTT assay. In total six independent donor
for 30 min at 100°C followed by slowly cooling to room
experiments were performed in which 3–12 punch biop-
temperature and washing in PBS. For keratin 10 and
sies were analyzed from each 150-cm2 area of EC-
cytokeratin only, an additional protease digestion step Matriderm. All biopsies contained viable cells. The in-
with 4 mg/ml pepsin in 0.2 M HCl was performed for terdonor and intradonor variability was very low (mean
15 min at room temperature. Immunohistochemical OD 0.21 ± 0.01 and 0.23 ± 0.03, respectively), indicat-
analysis of melanoma-associated antigen (NKI/beteb, ing that the protocol was highly reproducible and robust
IgG2b, Monosan, Uden, The Netherlands) was per- (Fig. 2).
formed using 5-µm frozen sections that were air-dried In order to determine the distribution of epidermal
and fixed in acetone for 10 min prior to incubation with keratinocytes within the EC-Matriderm, 3-mm biopsies
the primary antibody. After fixation and antigen re-
were taken for immunohistochemical staining with anti-
trieval, sections were washed in PBS, incubated with
cytokeratin. Individual keratinocytes were distributed
primary antibody for 1 h at room temperature followed
evenly over the seeding surface of the carrier (Fig. 3b).
by incubation with avidin-biotin-peroxidase complex Penetration into the carrier was limited and no keratino-(Envision+ System, Dako). All sections were washed in
cytes were observed on the lower surface of the carrier.
PBS and were counterstained with hematoxylin. Notably, no differentiating keratinocyte clones were ob-
served, indicating that the Matriderm carrier is enrichedStatistical Analysis
with proliferating, undifferentiating keratinocytes.All data are presented as mean ± SEM. The number
of experiments that represent different donors with inter-
Transport Conditions for EC-Matriderm
nal duplicates is stated in the figure legends. Statistical
When considering a future clinical application forcalculations were performed as follows: two-way ANOVA
EC-Matriderm it is important to predefine the transportwith Bonferroni posttest was performed using GraphPad
conditions. Therefore, we determined whether EC-Prism version 4.00 for Windows (GraphPad Software,
Matriderm could remain outside of the culture incubatorSan Diego, CA, USA, www.graphpad.com). Differences
for a period of 24 h without any long-term adverse ef-were significant when *p < 0.05, **p < 0.01, and ***p <
fects occurring with regards to EC metabolic activity0.005 relative to control.
and viability (Fig. 4). When EC-Matriderm was placed
RESULTS
under transport conditions (HBSS, 20°C, atmospheric
Epidermal Cell Amplification oxygen and humidity) for 24 h, a slight decrease in met-
abolic activity was observed compared to parallel con-A coculture of keratinocytes and melanocytes was
expanded from 1 cm2 of healthy skin derived from six trol cultures. However when EC-Matriderm was trans-
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Table 1. Amplification of Epidermal Cells Isolated From 1 cm2 of Skin
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6
(Female) (Male) (Female) (Male) (Male) (Male) Mean ± SEM
Age (years) 69 24 27 39 20 50 38.2 ± 7.6
P0 (×106 cells) 2.3 2.2 4.5 2.1 3.0 3.0 2.9 ± 0.4
P1 (×106 cells) 2.1 2.6 7.8 3.9 7.7 3.5 4.6 ± 1.0
P2 (×106 cells) 11.0 11.2 33.9 10.1 20.6 9.0 16.0 ± 4.0
Area covered (cm2/cm2 donor skin) 220 224 678 202 412 180 319.0 ± 79.4
P0: number of cells isolated from 1 cm2 of skin. P1: number of cells derived from original 1-cm2 skin biopsy after first amplification step
at time first passage (day 8–9). P2: number of cells derived from original 1-cm2 skin biopsy after second amplification step at time second
passage (day 10–14). Area covered: total area (cm2) that can be covered from cells amplified from the original 1-cm2 skin biopsy at time
of second passage (cm2/cm2 donor skin).
ferred from transport conditions back to optimum duplicates) (Fig. 3d). Histological analysis showed that
the reconstructed epidermis was fully differentiated andculture conditions again a full recovery was observed,
indicating no long-lasting negative effects due to the contained a compact basal layer of cells, a stratum
spinosum, stratum granulosum, and stratum corneumtransport conditions. Indeed, the metabolic activity was
greater than at the beginning of the experiment, indicat- (Fig. 5). Melanocytes (NKI-beteb staining) and prolifer-
ating cells (Ki67 staining) were located throughout theing that the cultures were actively growing again after
transport. basal layer at a similar frequency to that found in native
skin. Epidermal differentiation was normal as shown by
Transfer of Epidermal Cells From EC-Matriderm keratin 10 immunostaining. Only keratin 6 immuno-
to Dermis Results in Epidermal Regeneration staining was clearly different in that it was expressed
suprabasally in the regenerated epidermis whereas it wasNext the cell-seeded surface of EC-Matriderm was
placed in contact with human dermis and cultured for 3 absent in native epidermis.
days air exposed (Fig. 3c). Hereafter, the EC-Matriderm
DISCUSSIONwas removed and it was determined whether epidermal
cell transfer had occurred to such a degree that the epi- This study describes a potential novel cell culture,
transport, and transfer protocol that may be suitable fordermis could be regenerated. Indeed, epidermis regener-
ated with a 100% success rate with no epidermal blister- delivering cultured proliferating EC to large open skin
wounds. In this in vitro study, we have taken into ac-ing: no separation of the epidermis from the basement
membrane (three independent donors each with internal count the amplification factor of the cultured EC, the
Figure 2. Metabolic activity of EC-Matriderm. Metabolic activity representing cell viability of 3-
mm-diameter punch biopsies derived from EC-Matriderm. Each point represents the mitochondrial
activity of one biopsy. The line indicates the average value for a particular donor. The bar indicates
the mean of all six donors ± SEM. No significant difference was observed between the donors.
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composition of the culture medium with respect to regu-
latory issues, the type of transport carrier used, and the
success rate of epidermal regeneration after transfer to
human dermis.
This study included a slight refinement of the culture
medium [compared to our previous study (7)] in order
for the EC-Matriderm to comply with the regulations set
by the Dutch Central Committee on Research Involving
Human Subjects (CCMO) as suitable for human clinical
studies, our future aim. Therefore, we first confirmed
that the amplification factor of the cultured EC was still
in the same order of magnitude as our previous study.
Indeed, enough EC could be cultured from 1 cm2 of skin
to produce 319 ± 79 cm2 EC-Matriderm, which corre-
lated closely to our previously reported 400-fold ampli-
fication factor. This amplification factor is somewhat
less than that reported by the Rheinwald and Green
method (600-fold). This is most likely to be due to the
absence of 3T3 feeder cells in our method. However, it
should also be noted that it takes 3–4 weeks of culture
to obtain this amplification factor and a confluent sheet
suitable for transplantation compared to the 2-week cul-
ture protocol described in this study (12). Our shortened
culture protocol is extremely beneficial when consider-
ing treating burns patients with autologous EC.
In our study we chose Matriderm as a transport car-
rier for the EC. This 3D matrix is registered as a medical
device and has previously been used in clinical studies
for stimulating dermal regeneration in severe burns
(15,26). Here we describe a potentially novel application
for this commercially available artificial matrix. Seeding
EC onto Matriderm makes it possible to transport and
transfer keratinocytes as single proliferating, undifferen-
tiated cells with good regenerative potential. This is
favorable above transporting and transferring differenti-
ated keratinocytes, which have low regenerative poten-
tial. Our method was reproducible and showed little in-
ter- and intraexperimental variation with regards to
location and number of viable cells within the Matri-
derm. Other investigators have also realized the potential
of transporting single proliferating keratinocytes to the
wound rather than confluent differentiated EC cultures.
A number of strategies have been used for delivering
subconfluent keratinocytes onto a wound bed. One of
these is to spray a suspension of epidermal cells onto
the wound with the aid of a nozzle cell spray apparatus
(19). Although this is a very attractive technique, it doesFigure 3. Culture and transfer of epidermal cells onto human
have a number of potential disadvantages above ourdermis. (a) A representative epidermal cell culture undergoing
amplification. (b) Immunohistochemical staining of EC- method. The primarily disadvantage is that keratinocytes
Matriderm with anti-human cytokeratin shows distribution of in suspension undergo terminal differentiation if lacking
keratinocytes within the Matriderm carrier. (c) Transfer of epi-
cell–cell and cell–substratum contacts for even a limiteddermal cells from EC-Matriderm (1 cm2) by placing EC-
period of time (<1 h) (1,9,23,28). This means that theMatriderm onto acellular human dermis for 3 days. (d) The
keratinocytes cannot be transported from a culture facil-regenerating, as yet unpigmented, epidermis is visible as a yel-
low layer on the dermis after 2 weeks culture. ity outside of the hospital and that in general this tech-
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Figure 4. Transport conditions for EC-Matriderm. The bars represent the metabolic activity of 3-
mm-diameter punch biopsies derived from EC-Matriderm obtained at different time intervals dur-
ing transport and recovery. A: metabolic activity of EC-Matriderm cultured at optimal conditions
before transport; B: metabolic activity of EC-Matriderm placed at ambient conditions for 24 h;
and C: metabolic activity of EC-Matriderm placed at ambient conditions for 24 h and then cultured
under optimal conditions for a further 48 h. The bars indicate the mean of 10 biopsies each derived
from three donors ± SEM. ***p < 0.005 relative to control (A).
nique is applied in a one-step protocol, without EC am- tute and to transplant this entire construct containing liv-
ing cells (keratinocytes and fibroblasts) and the dermalplification. The skin is excised and epidermal cells are
isolated and then sprayed directly onto the wound, all matrix onto the wound bed. In contrast to transport car-
rier systems, the dermal matrix is incorporated into thewithin the time allotted to surgery. Obviously this de-
mands time and expertise unrelated to patient care from wound bed rather than being discarded after autologous
cell transfer. A number of clinical studies have been de-clinicians. A further drawback with spraying keratino-
cytes in suspension onto the wound bed is the risk of an scribed in which autologous skin substitutes have been
used to treat deep burns (4,18) and chronic ulcersuneven delivery, particularly if the wound bed is not
entirely horizontal. The use of EC-Matriderm potentially (10,27). Matriderm has been used as a dermal matrix in
a preclinical study for the in vitro construction of a skinovercomes both of these problems because the single
proliferating keratinocytes do not undergo rapid terminal substitute (11). Whereas these studies look promising,
the logistics around amplifying both autologous celldifferentiation due to their cell–substratum contacts, and
furthermore the EC-Matriderm is designed to be applied types (keratinocytes and fibroblasts) in a limited time
period in order to construct enough skin substitutes toas a living dressing onto the wound bed.
Other investigators have treated burns with cultured cover large wounds, as well as the transport conditions
still remain important issues.autologous keratinocytes suspended in fibrin glue (17).
Again a drawback with this method lies with the possi- In this study we were able to show that EC within
the EC-Matriderm were transferred to human dermisbility of uneven delivery. A limited number of transport
carrier systems have been described (6). Polyurethane within 3 days to such an extent that fully differentiated
human epidermis regenerated within 2 weeks. This 3-wound dressings and the dermal regeneration template
IntegraTM have been used to transfer keratinocytes to day transfer period was decided after considering the
logistics of a future clinical application and would corre-athymic mice (29) and pigs (16,25). The eventual imple-
mentation of these carrier systems, together with our spond with the time between applying the EC-Matrid-
erm to a patient and the first dressing change after trans-proposed carrier, will depend on future studies describ-
ing the clinical outcome of multicenter trials and the plantation. The regenerated epidermis showed no signs
of blistering (no separation of the epidermis from thecosts of the transport carrier.
An alternative method to transplant keratinocytes basement membrane) and contained a compact basal
layer of cells, stratum spinosum, stratum granulosum,onto a wound bed is to construct in vitro a skin substi-
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Figure 5. Cultured regenerated epidermis (cultured for 14 days) closely resembles healthy native skin. A fully differentiated
epidermis is shown by hematoxylin and eosin staining (H/E). Immunohistochemical staining for melanocytes (anti-NKI-beteb),
proliferating cells (anti-Ki67), differentiating cells (anti-keratin 6), and activated epidermis (anti-keratin 10) is shown. Scale bars:
50 µm.
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members of the fos and jun families and myc networkand stratum corneum. Furthermore, melanocytes repopu-
during terminal differentiation of human keratinocytes.lated the basal layer indicating that EC-Matriderm has Oncogene 11:1403–1407; 1995.
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ments? Burns 24:591–593; 1998.
mis. Our in vitro study has produced a robust protocol 15. Haslik, W.; Kamolz, L. P.; Nathschlager, G.; Andel, H.;
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